| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC1788 |
| Trial ID | NCT03289455 |
| Disease | B-Cell Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia | Childhood B-Cell Acute Lymphoblastic Leukemia | Childhood Acute Lymphoblastic Leukemia |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | AUTO3 |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL) |
| Year | 2017 |
| Country | United Kingdom |
| Company sponsor | Autolus Limited |
| Other ID(s) | AUTO3-PA1|2016-004680-39 |
| Cohort 1 | |||||||
|
|||||||